Darling Ingredients Inc. Common Stock vs Novo Nordisk A/S — how do they compare? Darling Ingredients Inc. Common Stock trades at $60.18 (market cap $9.82B), while Novo Nordisk A/S trades at $38.38 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 16.8× Darling Ingredients Inc. Common Stock's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Darling Ingredients Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Darling Ingredients Inc. Common Stock for 0 Days and Novo Nordisk A/S for 116 Days on average.
| DAR | NVO | |
|---|---|---|
Market Cap | $9.82B | $165.31B |
Volume | 2,815,184 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $68.34 | $63.98 |
52-Week Low | $29.91 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $13.83B | $179.56B |
Dividend Yield | — | 4.71% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Darling Ingredients collects and processes used cooking oil, animal by-products, and food waste. It produces ingredients and renewable fuel feedstocks from these materials.
Read more on DAR →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →